

Press release 2012-08-29



US patent granted for the C-RAD Catalyst™ system

C-RAD AB with its three fully owned subsidiaries in Sweden and three international sales companies are all active in the field of radiation therapy. The US Patent and Trademark Office has recently issued a comprehensive patent which protects the unique features of the Catalyst™ system on the US market.

The Catalyst™ is a next-generation high performance tracking system based on optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable clinicians to perform a real-time assessment of patient positioning errors before and during treatment delivery. Interfaces to major vendors ensure a completely integrated workflow.

The recently issued US patent will ensure that C-RAD maintains the exclusive right to market and sell solutions based on the advanced principles underlying the Catalyst™ system. The US radiation therapy market represents 50% of the total world market. At the same time, the US patent system is widely regarded as offering the best protection worldwide for new innovations.

Erik Hedlund, CEO, C-RAD AB:

"The new US patent again proves the innovative strength of the C-RAD group. In light of the remarkable interest received for the Catalyst™ system from end users as well as industrial partners, the patent forms a strong asset and will enable new sales as well as licensing opportunities."

For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46-(0)18-66 69 31, E-Mail erik.hedlund@c-rad.se

About C-RAD AB

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries in Sweden; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD has own sales companies in Germany, USA and China. The headquarter of the group is located in Uppsala, Sweden. Numbers of employees are currently 22 people. The activities at C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD AB is listed at Nasdaq Omx First North Premier.